Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Sustol, First Extended-Release 5-HT3 Approved for the Prevention of CINV

Online First - FDA Approvals, News & Updates

On August 10, 2016, the FDA approved granisetron extended-release (Sustol; Heron Therapeutics) injection, the first extended-release 5-hydroxytryptamine (5-HT3) receptor antagonist, in combination with other antiemetic drugs in adults, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide combination chemotherapy regimens.

This long-acting formulation of granisetron is delivered through the Biochronomer polymer-based technology that allows the drug to remain in the body at therapeutic levels for at least 5 days, during the acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV).

“Despite advances in the management of CINV, up to half of patients receiving chemotherapy can still experience CINV, with delayed CINV being particularly challenging to control. In our experience, other 5-HT3 receptor antagonists, including palonosetron, are generally effective for 48 hours or less. Sustol, due to its extended-release profile, represents a novel option that can protect patients from CINV for a full 5 days,” said Ralph V. Boccia, MD, FACP, Medical Director, Center for Cancer and Blood Disorders, in a press release.

The approval was based on 2 large clinical trials that evaluated granisetron’s efficacy and safety in the acute and delayed phases of CINV in more than 2000 patients with cancer. The primary end point was the complete response rate, which was defined as no emetic episodes and no use of rescue medications. In one trial, 200 patients who received granisetron extended-release after moderately emetogenic chemotherapy, 166 (83%) patients had a complete response in the acute phase of CINV, and 137 (69%) had a complete response in the delayed phase. And of 171 patients who received granisetron extended-release after anthracycline plus cyclophosphamide, 120 (70%) patients had complete response in the acute phase of CINV, and 85 (50%) patients had a complete response in the delayed phase of CINV.

The most common (≥3%) adverse reactions are injection-site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

 

Related Items
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
FDA News
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in FDA Approvals, News & Updates
Ivosidenib Now FDA-Approved as First-Line Treatment for AML with IDH1 Mutation
Web Exclusives published on May 7, 2019 in FDA Approvals, News & Updates, In the News
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
Web Exclusives published on April 23, 2019 in FDA Approvals, News & Updates, In the News
April 16, 2019 – FDA Approvals, News & Updates
Web Exclusives published on April 16, 2019 in FDA Approvals, News & Updates, In the News
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Web Exclusives published on April 5, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Web Exclusives published on April 1, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Web Exclusives published on March 22, 2019 in FDA Approvals, News & Updates, In the News, Lung Cancer
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Web Exclusives published on March 15, 2019 in FDA Approvals, News & Updates, In the News
March 08, 2019 – FDA Approvals, News & Updates
Web Exclusives published on March 8, 2019 in FDA Approvals, News & Updates, In the News
Last modified: November 11, 2016